-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that Sichuan Guorui Pharmaceutical's dexmedetomidine hydrochloride sodium chloride injection and dexmedetomidine hydrochloride injection have been accepted as imitation 3 types of listing applications
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
Dexmedetomidine is an α2-adrenergic receptor agonist, mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
.
.
Sales of terminal dexmedetomidine injections in public medical institutions in China (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
com, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
Dexmedetomidine injections include dexmedetomidine hydrochloride injection and dexmedetomidine hydrochloride sodium chloride injection
.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, dexmedetomidine hydrochloride injection has 9 companies including Jiangsu Zhengda Qingjiang Pharmaceutical, Tianfang Pharmaceutical, and CommScope Pharmaceuticals, etc.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
Source: CDE official website, Minet.
com database
com database
A few days ago, the CDE official website showed that Sichuan Guorui Pharmaceutical's dexmedetomidine hydrochloride sodium chloride injection and dexmedetomidine hydrochloride injection have been accepted as imitation 3 types of listing applications
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
Dexmedetomidine is an α2-adrenergic receptor agonist, mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
.
.
Sales of terminal dexmedetomidine injections in public medical institutions in China (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
com, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
Dexmedetomidine injections include dexmedetomidine hydrochloride injection and dexmedetomidine hydrochloride sodium chloride injection
.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, dexmedetomidine hydrochloride injection has 9 companies including Jiangsu Zhengda Qingjiang Pharmaceutical, Tianfang Pharmaceutical, and CommScope Pharmaceuticals, etc.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
Source: CDE official website, Minet.
com database
com database
A few days ago, the CDE official website showed that Sichuan Guorui Pharmaceutical's dexmedetomidine hydrochloride sodium chloride injection and dexmedetomidine hydrochloride injection have been accepted as imitation 3 types of listing applications
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
.
According to data from Menet.
com, the sales of terminal dexmedetomidine injections in China's public medical institutions in 2020 will be close to 4 billion yuan, with a year-on-year growth of more than 10% in 2021H1.
Among them, Yangzijiang Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks No.
Two people
.
Dexmedetomidine is an α2-adrenergic receptor agonist, mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
.
.
Sales of terminal dexmedetomidine injections in public medical institutions in China (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
Hospital Hospital Hospital Medicine Medicine Medicine Medicinecom, in 2020, the sales of terminal dexmedetomidine injections in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 4 billion yuan, with a year-on-year increase of more than 10%, Yangtze River Pharmaceutical Group has the largest market share, and Jiangsu Hengrui Pharmaceutical ranks second
.
Dexmedetomidine injections include dexmedetomidine hydrochloride injection and dexmedetomidine hydrochloride sodium chloride injection
.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
Enterprise business enterprise.
Among them, dexmedetomidine hydrochloride injection ranked second in the TOP10 neurochemical drug products
.
Currently, dexmedetomidine hydrochloride injection given manufacturers have 16, which, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Jiangsu En Hua Pharmaceutical, Chengdu Brilliant Pharmaceutical and other super 10 enterprises through assessment; the right of hydrochloric acid The manufacturers of Medetomidine Sodium Chloride Injection include Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for the production of imitation 3 types, which are deemed to have been reviewed
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In addition, dexmedetomidine hydrochloride injection has 9 companies including Jiangsu Zhengda Qingjiang Pharmaceutical, Tianfang Pharmaceutical, and CommScope Pharmaceuticals, etc.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
, which are under review and approval; dexmedetomidine hydrochloride sodium chloride injection has Yangzijiang medicine.
Three companies, including the Industrial Group and Hunan Kelun Pharmaceutical, are under review and approval
.
Source: CDE official website, Minet.
com database
com database
